CancerFax

08/04/2026

CAR-T therapy is one of the most talked-about advances in cancer treatment, but it is also one of the most misunderstood.

It is not a general treatment for every cancer.
It is not a magic solution.
And it is not suitable for every patient.

But in the right case, under the right team, it can be a very important option to evaluate.

The most important thing families need is not hype. It is understanding.

Save this post if you want more simple breakdowns of advanced cancer treatments.

Comment CAR-T if you want us to do a post on who may be considered for it.

06/04/2026

06/04/2026

When a family hears the word "cancer," the next few days often become a blur of fear, urgency, confusion, and rushed decisions.

That is precisely why CancerFax exists.

We help patients and families understand advanced treatment options, explore second opinions, and access global cancer care pathways when local options feel limited, unclear, or exhausted.

We are not here to create false hope. We are here to create clarity.
Because in cancer care, the right information at the right time can change everything.

Follow CancerFax for clear, compassionate, science-led guidance on advanced cancer treatment options.

Comment GUIDE if you want us to create more content on what families should do first after diagnosis.

04/04/2026

India’s oncology NGS market is projected to grow at 17%+ CAGR through 2030.

But what does that number actually mean for practising oncologists?
Here’s the landscape:
• India sees over 14 lakh new cancer cases annually. Rising.
• Only a small fraction currently receives comprehensive genomic profiling.
• The market had just 2–3 NGS players in 2015. Today, there are 13–14 providers.
• Sequencing costs have dropped dramatically, making NGS increasingly feasible.
• Government initiatives like dbGENVOC and the Union Budget 2025–26 for cancer care provisions are building the infrastructure.

But here’s the gap:

Metro cities still heavily concentrate on NGS adoption. Limited access to NGS is available in Tier-2 and Tier-3 centers, where a significant proportion of cancer patients receive treatment.

The technology is ready. The guidelines support it. The market is growing.

The question now is, how do we bridge the last mile?
That’s a question we think about every day at CancerFax. And we’d love to hear your perspective.

29/03/2026

🚀 Exciting News in Cancer Treatment! 🚀

The FDA has now approved Hernexeos (zongertinib) as the first treatment option for adults with HER2-Mutant non-small cell lung cancer. This breakthrough means that 76% of patients saw their tumors shrink, offering new hope and improved outcomes for many.

Stay informed with CancerFax Insights, your trusted source for the latest in cancer care and oncology.

Read more about this significant advancement here: https://cancerfax.beehiiv.com/p/fda-expands-approval-of-hernexeos-for-first-line-her2-mutant-lung-cancer-76-of-patients-saw-tumors-s

28/03/2026

🎗️ Welcome to CancerFax Insights 🎗️

Are you or a loved one dealing with the complicated world of cancer care? You're not alone. CancerFax Insights is here to guide you through the maze of medical jargon and treatment options. Our mission is simple: connect you with the most advanced cancer treatments available worldwide, regardless of where you live.

🌍 What is CancerFax?

CancerFax is your gateway to cutting-edge treatments like CAR-T cell therapy, TIL therapy, stem cell therapy, and global clinical trials.

We collaborate with top hospitals and cancer experts in countries like India and China to ensure you have access to the latest breakthroughs.

📰 What you'll find in CancerFax Insights:

- 🔬 Breakthrough research: Stay updated with the latest developments in cancer care.
- 🌟 Expert insights: Learn from the best minds in oncology.
- 🌐 Global perspective: Discover treatments and trials happening around the world.

Join our community and empower yourself with knowledge. Together, we can navigate the path to better cancer care.

Read more: https://cancerfax.beehiiv.com/p/welcome-to-cancerfax-insights

Your window into the world of advanced cancer care

27/03/2026

We’ve been talking about why NGS matters. Now I want to hear from you.
What is your BIGGEST barrier to ordering testing for your patients?

💰 Cost—it's too expensive for most patients
⏰ Turnaround time — results take too long to be clinically useful
📍 Availability — no reliable NGS lab accessible to me
📊 Interpretation — I’m not sure how to act on NGS results

Please enter your response in the comment box.

Every barrier has a solution. But we need to understand which barriers matter most to Indian oncologists RIGHT NOW.

Vote, and tell us more in the comments. Your input is directly shaping how we approach this problem at CancerFax.

20/03/2026

Let me tell you about a patient. (This is a composite case for illustration.)

A 52-year-old woman. She was diagnosed with advanced adenocarcinoma of the lung. Never a smoker. She had already failed two lines of chemotherapy. Her oncologist was running out of options. Immunotherapy was tried but didn’t work; her PD-L1 was low.

Then someone suggested comprehensive genomic profiling.

The NGS report came back with a finding that changed everything: an NTRK fusion. NTRK fusions are rare, found in only 1–2% of common cancers. They would NEVER be detected by standard single-gene testing panels.

But here’s the thing: NTRK fusions have FDA-approved targeted therapies (larotrectinib, entrectinib) with response rates above 75%. Across all tumor types.

This patient was started on targeted therapy. Her tumors began shrinking within weeks. Without NGS, this mutation would never have been found. The discovery of this mutation would have left this patient with no effective treatment options.

Such a discovery is not a miracle. This is precision oncology. Such precision is what NGS makes possible.

How many patients like this type of testing are we missing?

If this story resonates, share it. Every oncologist deserves to know what genomic testing can reveal.

14/03/2026

What do NCCN guidelines say about NGS in 2026?

If you’re an oncologist wondering whether NGS is “recommended” or just “nice to have," let the guidelines speak.

Here’s a summary of current NCCN recommendations for comprehensive genomic profiling:

NSCLC (Non-Small Cell Lung Cancer):
“Broad molecular profiling is recommended for all patients with advanced NSCLC.”
That means NGS is not a sequential single-gene testing.

Breast Cancer:
Germline BRCA1/2 testing for all eligible patients. Somatic PIK3CA, ESR1, and HER2 testing for advanced disease. NGS panels capture all of these in one test.

Colorectal Cancer:
Universal MMR/MSI testing. RAS and BRAF testing for metastatic disease. HER2 amplification assessment. NGS covers the full panel.

Ovarian Cancer:
Germline and somatic BRCA + HRD testing for all patients with epithelial ovarian cancer. This testing is crucial in making decisions about PARP inhibitors.

Hematological Malignancies:
AML: FLT3, IDH1/2, NPM1, TP53 at diagnosis. ALL: Broad molecular characterization. CML: BCR-ABL monitoring.

The message from global guidelines is clear: comprehensive genomic testing is no longer optional for quality cancer care. It's a must.

10/03/2026

Here’s a number that should change how we think about cancer treatment:

NGS results change the treatment plan in 30–40% of advanced cancer cases.

Let that sink in. For roughly 1 in 3 patients with advanced cancer, comprehensive genomic profiling reveals something that directly alters the course of treatment.

What does “change the treatment plan” actually mean?

• A patient scheduled for standard chemotherapy gets matched to a targeted therapy with better outcomes and fewer side effects.
• A patient with no known options gets identified for a clinical trial based on a rare but druggable mutation.
• A patient is spared an ineffective treatment because their molecular profile predicts resistance.

This isn’t theoretical. This is published evidence from studies across lung, breast, colorectal, and ovarian cancers.

In India, where we see over 14 lakh new cancer cases every year, this translates to lakhs of patients who could benefit from precision diagnostics.

The question isn’t whether NGS works. It’s whether we can afford not to use it.

What’s your experience? Have genomic results ever changed your treatment approach?

09/03/2026

✨ A powerful example of what precision oncology can achieve ✨

A published clinical case from China showed a patient with huge, unresectable hepatocellular carcinoma (HCC) achieving a remarkable and long-lasting response using p53 gene therapy (Gendicine®) combined with TACE and chemotherapy.

🔬 Key highlights:
• Tumor size reduced from 16 × 13.5 cm to just 3 × 2 cm
• AFP levels dropped from 12,947 to normal
• Liver function remained stable
• Disease control sustained for over 600 days

This case reinforces the role of TP53-targeted gene therapy in sensitizing tumors to chemotherapy and improving outcomes in advanced HCC patients who are not surgical candidates.

📚 Published in Anti-Cancer Drugs (2009)

As oncology moves beyond one-size-fits-all treatments, gene therapy is redefining what’s possible in advanced liver cancer.

06/03/2026

Every cancer has a genetic story behind it. NGS, or next-generation sequencing, helps us read that story and choose therapies that truly match the biology of the disease, allowing for personalized treatment plans that can significantly improve patient outcomes.

At CancerFax, we strongly believe genomic testing should become a routine part of cancer care so patients can access the most precise and effective treatment options available today.

From DNA to Drug Selection: How NGS Actually Works?

Your patient has advanced cancer. You suspect there might be a targeted mutation. Here’s what happens when you order NGS (next-generation sequencing):

Step 1: Sample Collection
Tumor tissue (biopsy or surgical specimen) or a liquid biopsy (blood draw) is collected.

Step 2: DNA Extraction
Genomic DNA is extracted from tumor cells and fragmented into millions of small pieces.

Step 3: Library Preparation
DNA fragments are tagged and prepared for sequencing. Target genes are captured using a panel (e.g., 300–500 cancer-related genes).

Step 4: Sequencing
Millions of DNA fragments are read simultaneously; this is the “next-generation” part. Unlike Sanger sequencing (1 gene at a time), NGS reads thousands of genes in parallel.

Step 5: Bioinformatics Analysis
Sophisticated algorithms compare the tumor DNA to a reference genome, identifying mutations, fusions, copy number changes, TMB, and MSI status.

Step 6: Clinical Report
Results are compiled into an actionable report: which mutations were found, which therapies they respond to, and which clinical trials are available.

The entire process takes 7–14 days from sample to report.

One test. Hundreds of answers. That’s the power of NGS.

Save this post. Share it with a colleague who’s curious about genomic testing.